CTNM earnings analysis
What we found in CTNM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Contineum Therapeutics reported a net loss of $14.5 million for Q1 2026, an improvement from $16.0 million in Q1 2025, primarily due to reduced R&D expenses which fell by 15%. Despite no revenue from product sales, the company maintains a strong cash position of $246.3 million, sufficient to support operations through mid-2029.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Improvement
- Net loss decreased to $14.5 million in Q1 2026 from $16.0 million in Q1 2025, a $1.5 million improvement.
- R&D Expenses Decrease
- R&D expenses decreased by 15% to $11.6 million in Q1 2026 from $13.7 million in Q1 2025.
- Strong Cash Position
- Cash, cash equivalents, and marketable securities totalled $246.3 million as of March 31, 2026.
- R&D Costs Breakdown
- Direct external development costs for PIPE-791 were $6.05 million compared to $5.55 million in Q1 2025.
- Interest Income Increase
- Interest income increased to $2.5 million in Q1 2026 from $2.3 million in Q1 2025.
- Improved Operating Loss
- Loss from operations improved to $16.9 million in Q1 2026, compared to $18.1 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Financial Losses
- The company continues to operate at a net loss of $14.5 million for Q1 2026.
- Dependency on Drug Candidates
- Future success is heavily reliant on the clinical development of drug candidates like PIPE-791 and PIPE-307.
- Increased Operating Expenses Expected
- Operating expenses are expected to rise as the company scales its clinical trial activities.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.54
What they said about what is next.
No numeric guidance for revenue or EPS was provided.
The filing reads better than the one before it.
What came before.
- 10-K · March 5, 2026
- Contineum is a clinical-stage biopharma focused on small-molecule NI&I therapies. Key positives: PIPE-791 advanced into a 26-week Phase 2 (PROPEL‑IPF) in December 2025 with ~324 subjects after positive Phase 1b PET data…
- 10-Q · October 30, 2025
- Contineum reported a three-month net loss of $12,792,000 (EPS -$0.45) for the quarter ended September 30, 2025, with operating expenses rising to $14,932,000 from $12,974,000 a year ago. Liquidity remains strong: cash…
- 10-Q · August 5, 2025
- Contineum reported a Q2 net loss of $(16,040) (three months ended June 30, 2025) and EPS of $(0.62), wider than prior-year Q2 EPS of $(0.39). Operating expenses rose to $17,902 (three months) driven by higher R&D of…
- 10-Q · May 14, 2025
- Contineum reported no product revenue and a larger operating cost base in Q1 2025, driving a net loss of $(15,990) (as reported) and GAAP EPS of $(0.62). R&D spend rose materially to $13,712 versus $7,778 in Q1 2024,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CTNM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever